136 related articles for article (PubMed ID: 37154316)
1. [Advances of glioma biomarkers].
Hao M; Liang Y; Guo R; Li X; Li Y; Wang L; Yu C; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1445-1461. PubMed ID: 37154316
[TBL] [Abstract][Full Text] [Related]
2. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
[TBL] [Abstract][Full Text] [Related]
3. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
4. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
6. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
8. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
10. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
11. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
12. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
13. Progress in the application of molecular biomarkers in gliomas.
Wang J; Su HK; Zhao HF; Chen ZP; To SS
Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
[TBL] [Abstract][Full Text] [Related]
14. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
Brandner S; von Deimling A
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
[TBL] [Abstract][Full Text] [Related]
16. Updates in prognostic markers for gliomas.
Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
[TBL] [Abstract][Full Text] [Related]
17. Molecular Characteristics of Thalamic Gliomas in Adults.
Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
[TBL] [Abstract][Full Text] [Related]
18. The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
Vuong HG; Nguyen TQ; Ngo TNM; Nguyen HC; Fung KM; Dunn IF
BMC Cancer; 2020 Sep; 20(1):897. PubMed ID: 32957941
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
Siegal T
Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407
[TBL] [Abstract][Full Text] [Related]
20. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
